Long Grove Pharmaceuticals is debuting triamcinolone acetonide injectable suspension.
The product, which is indicated for intramuscular and intra-articular use for multiple conditions including the treatment of various types of arthritis, is a generic of Bristol Myers Squibb’s Kenalog-40.
It is available in both single-dose and multiple-dose vial presentations, and its vial stopper does not contain natural rubber latex.
“We are excited about the launch of Triamcinolone Acetonide,” said president and CEO Dan Robins. “This successful launch required hard work from the entire team here at Long Grove. We are proud of this significant accomplishment and look forward to further expanding our portfolio.”